Lumexa Imaging (NASDAQ: LMRI) received a significant boost on Monday as analysts at Raymond James Financial upgraded the company’s stock from an “outperform” rating to a “strong-buy” rating. This upgrade comes with a price target of $23.00, indicating a potential upside of 112.96% from Lumexa’s current trading price.
The stock opened at $10.80 on the day of the announcement and has seen an increase of 6.5%. Over the past year, Lumexa Imaging’s share price has fluctuated, reaching a low of $9.97 and a high of $19.45.
Recent Institutional Investment
In addition to the positive rating from Raymond James, Lumexa Imaging has attracted institutional interest. According to disclosures made to the Securities and Exchange Commission, Assetmark Inc. acquired a new position in Lumexa during the fourth quarter. The firm purchased 1,957 shares, valued at approximately $36,000. This investment reflects growing confidence in Lumexa Imaging’s future prospects.
About Lumexa Imaging
Lumexa Imaging is recognized as one of the largest national providers of diagnostic imaging services in the United States. The company’s platform is noted for being integrated and scalable, with a proven track record of delivering value to its stakeholders. As of September 30, 2025, Lumexa and its affiliates operate the second-largest outpatient imaging center footprint in the country, comprising 184 centers across 13 states. This extensive network includes eight joint venture partnerships with various health systems, strategically located in attractive metropolitan statistical areas.
As Lumexa Imaging continues to gain recognition in the diagnostic imaging sector, the recent upgrade by Raymond James Financial may further bolster investor confidence and support the company’s growth trajectory.
